Rosiglitazone reduces tau phosphorylation via JNK inhibition in the hippocampus of rats with type 2 diabetes and tau transfected SH-SY5Y cells

Rosiglitazone reduces tau phosphorylation via JNK inhibition in the hippocampus of rats with type 2 diabetes and tau transfected SH-SY5Y cells

Increasing evidence supports an association between Alzheimer's disease (AD) and diabetes. Rosiglitazone, a peroxisome proliferator-activated receptor-γ (PPARγ) agonist, which is an anti-diabetic agent against type 2 diabetes, is currently in Phase III clinical trials in AD patients because ros...

Full description

Bibliographic Details
Main Authors:	Seung-Yong Yoon, Jeong-Su Park, Jung-Eun Choi, Jin-Myung Choi, Woo-Je Lee, Seong-Who Kim, Dong-Hou Kim
Format:	Article
Language:	English
Published:	Elsevier 2010-11-01
Series:	Neurobiology of Disease
Subjects:	Alzheimer's disease Diabetes Tau phosphorylation Rosiglitazone PPARγ
Online Access:	http://www.sciencedirect.com/science/article/pii/S0969996110002299

Similar Items

Effect of Rosiglitazone on Coronary Angiogenesis in Diabetic and Control Rats
by: Ensieh Salehi, et al.
Published: (2011-06-01)

Dysregulated Brain Protein Phosphorylation Linked to Increased Human Tau Expression in the hTau Transgenic Mouse Model
by: Isidro Ferrer, et al.
Published: (2022-06-01)

Inhibitory effect and mechanism of Rosiglitazone on M1 type polarization of central microglia in intracerebral hemorrhage mice based on JNK/STAT3 signaling pathway
by: Chenglei Chao, et al.
Published: (2023-12-01)

The Evolution of Tau Phosphorylation and Interactions
by: Nataliya I. Trushina, et al.
Published: (2019-09-01)

Effects of Taurine on Phosphorylated Tau Protein Level in the Hippocampus of Scopolamine-Treated Adult Male Rats
by: Zeinab Asadi, et al.
Published: (2018-09-01)

Phosphorylation of tau at Y18, but not tau-fyn binding, is required for tau to modulate NMDA receptor-dependent excitotoxicity in primary neuronal culture
by: Takashi Miyamoto, et al.
Published: (2017-05-01)

Soluble P‐tau217 reflects amyloid and tau pathology and mediates the association of amyloid with tau
by: Niklas Mattsson‐Carlgren, et al.
Published: (2021-06-01)

Functional Interactions of Tau Phosphorylation Sites That Mediate Toxicity and Deficient Learning in Drosophila melanogaster
by: Iason Keramidis, et al.
Published: (2020-10-01)

Phosphorylation of Tau at S422 is enhanced by Aβ in TauPS2APP triple transgenic mice
by: Fiona Grueninger, et al.
Published: (2010-02-01)

Tau oligomers
by: Naruhiko eSahara, et al.
Published: (2014-01-01)

Specific binding of Hsp27 and phosphorylated Tau mitigates abnormal Tau aggregation-induced pathology
by: Shengnan Zhang, et al.
Published: (2022-09-01)

Phosphorylation of Tau and α-Synuclein Induced Neurodegeneration in MPTP Mouse Model of Parkinson’s Disease
by: Hu S, et al.
Published: (2020-03-01)

Rosiglitazone suppresses RANKL‐induced NFATc1 autoamplification by disrupting the physical interaction between NFATc1 and PPARγ
by: Kyeong‐Lok Park, et al.
Published: (2018-10-01)

Rosiglitazone Inhibits HMC-1 Cell Migration and Adhesion through a Peroxisome Proliferator-Activated Receptor Gamma-Dependent Mechanism
by: Guqin Zhang, et al.
Published: (2014-02-01)

Internalization of the Extracellular Full-Length Tau Inside Neuro2A and Cortical Cells Is Enhanced by Phosphorylation
by: Mathilde Wauters, et al.
Published: (2016-08-01)

Ultrasensitive assays for detection of plasma tau and phosphorylated tau 181 in Alzheimer’s disease: a systematic review and meta-analysis
by: Xulong Ding, et al.
Published: (2021-03-01)

Novel Conformation-Dependent Tau Antibodies Are Modulated by Adjacent Phosphorylation Sites
by: Giavanna Paterno, et al.
Published: (2023-09-01)

Editorial: Tau Protein: Mechanisms From Health to Degeneration
by: Isabel Lastres-Becker, et al.
Published: (2021-11-01)

Rosiglitazone ameliorates diffuse axonal injury by reducing loss of tau and up-regulating caveolin-1 expression
by: Yong-lin Zhao, et al.
Published: (2016-01-01)

Effect of exogenous trivalent iron ions on tau phosphorylation and aggregation in SH-SY5Y cells
by: Zhina ZHANG, et al.
Published: (2023-03-01)

Tau Phosphorylation in Female Neurodegeneration: Role of Estrogens, Progesterone, and Prolactin
by: Daniel Muñoz-Mayorga, et al.
Published: (2018-03-01)

Absence of a Role for Phosphorylation in the Tau Pathology of Alzheimer’s Disease
by: Robert Y. K. Lai, et al.
Published: (2016-04-01)

Interaction of Tau with Fe65 links tau to APP
by: Christian Barbato, et al.
Published: (2005-03-01)

Phosphorylated Tau in Alzheimer’s Disease and Other Tauopathies
by: Priyanka Rawat, et al.
Published: (2022-10-01)

Antisense Oligonucleotide-Mediated Reduction of HDAC6 Does Not Reduce Tau Pathology in P301S Tau Transgenic Mice
by: Antonio Valencia, et al.
Published: (2021-06-01)

PHF-Core Tau as the Potential Initiating Event for Tau Pathology in Alzheimer’s Disease
by: Nabil Itzi Luna-Viramontes, et al.
Published: (2020-09-01)

Modification of the Drosophila model of in vivo Tau toxicity reveals protective phosphorylation by GSK3β
by: Giulia Povellato, et al.
Published: (2013-11-01)

Differential regional distribution of phosphorylated tau and synapse loss in the nucleus accumbens in tauopathy model mice
by: Taiki Kambe, et al.
Published: (2011-06-01)

Constant Levels of Tau Phosphorylation in the Brain of htau Mice
by: Joerg Neddens, et al.
Published: (2020-08-01)

Pilot Study of the Total and Phosphorylated Tau Proteins in Early-Stage Multiple Sclerosis
by: Ieva Masiulienė, et al.
Published: (2024-02-01)

Rosiglitazone increases endothelial cell migration and vascular permeability through Akt phosphorylation
by: Yun Hyi Ku, et al.
Published: (2017-08-01)

A new TAO kinase inhibitor reduces tau phosphorylation at sites associated with neurodegeneration in human tauopathies
by: Caterina Giacomini, et al.
Published: (2018-05-01)

Small-molecule drug screening identifies drug Ro 31-8220 that reduces toxic phosphorylated tau in Drosophila melanogaster
by: Kyu-Ho Shim, et al.
Published: (2019-10-01)

Tau in MAPK activation
by: Chad J. Leugers, et al.
Published: (2013-10-01)

Exploring the Therapeutic Potential of Phosphorylated <i>Cis</i>-Tau Antibody in a Pig Model of Traumatic Brain Injury
by: Samuel S. Shin, et al.
Published: (2023-06-01)

Oxidative Stress Signaling in Blast TBI-Induced Tau Phosphorylation
by: Chunyu Wang, et al.
Published: (2021-06-01)

Expression of p-PPARγ in the aging thoracic aorta of spontaneously hypertensive rat and inhibitory effect of rosiglitazone
by: Hai-Feng Yuan, et al.
Published: (2014-12-01)

Cell-based Models To Investigate Tau Aggregation
by: Sungsu Lim, et al.
Published: (2014-11-01)

Tau protein and adult hippocampal neurogenesis
by: Almudena eFuster-Matanzo, et al.
Published: (2012-07-01)

“Tau immunotherapy: Hopes and hindrances”
by: Koorosh Shahpasand, et al.
Published: (2018-02-01)